Faculty

> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Basic and translational research in rare and common lung diseases: pulmonary lymphangioleiomyomatosis (LAM), tuberous sclerosis (TS), Birt-Hogg-Dube (BHD); Multicentric Castleman Disease (MCD), pulmonary arterial hypertension (PAH), asthma; Cellular signaling networks: phosphatidylinositol 3-kinase (PI3K), Akt, tumor suppressor complex TSC1/TSC2, protein translational regulation, mTOR,LKB1, AMPK, FLCN, RhoA GTPase, Rac1 GTPase, STAT3; Airway smooth muscle cell biology and remodeling,vascular smooth muscle cell biology and remodeling, cell growth, cell proliferation, cell migration, invasiveness; animal models of lung diseases.

Description of Clinical Expertise

Principal Investigator of the SOS (Safety Study of Simvastatin in Patients with Sporadic Pulmonary Lymphangioleiomyomatosis (LAM) and LAM Associated with Tuberous Sclerosis Complex) clinical trial (ClinicalTrials.gov Identifier: NCT02061397)

Description of Other Expertise

Marketing management, concert piano

Selected Publications

Obraztsova K, Mukhitov AR, Lin SM, Smith C, Basil MC, Katzen J, Carl J, Beers MF, Morrisey EE, Krymskaya VP: Upregulation of WNT signaling in lung epithelial-mesenchymal crosstalk may contribute to the cystic remodeling in Pulmonary Lymphangioleiomyomatosis(LAM). American Thoracic Society. American Thoracic Society, May 2021 Notes: Submitted for presentation at American Thoracic Society International Conference in May 2021.

Kovalenko A, Sanin A, Kosmas K, Zhang L, Wang J, Akl EW, Giannikou K, Probst CK, Hougard TR, Rue RW, Krymskaya VP, Asara JM, Lam HC, Kwiatkowski DJ, Henske EP, Filippakis H: Therapeutic targeting of DGKA-mediated macropinocytosis leads to phospholipid reprogramming in Tuberous Sclerosis Complex. Cancer Research 81: 2086-2100, April 2021 Notes: DOI: 10.1158/0008-5472.CAN-20-2218.

Evans JF, Obraztsova K, Lin SM, Krymskaya VP : CrossTORC and Wntegration in disease: Focus on Lymphangioleiomyomatosis. International Journal of Molecular Sciences 22: 2233-2248, February 2021 Notes: doi.org/10.3390/ijms22052233.

Li H, Oh HB, Viollet B, Schmidt LS, Linehan WM, Krymskaya VP, Hong SB: Requirement of FLCN tumor suppressor gene for mTORC1-mediated inhibition of TFE3 transcriptional activity. bioRxiv Jul 2020 Notes: doi: https://doi.org/10.1101/2020.07.08.193169.

Han F, Dellacecca ER, Barse LW, Cosgrove C, Henning SW, Ankney CM, Jaishankar D, Yemelyanov A, Krymskaya VP, Dilling DF, Le Poole IC: Adoptive T cell transfer to treat lymphangioleiomyomatosis. American Journal of Respiratory Cell and Molecular Biology 62(6): 793-804, Jun 2020 Notes: doi: 10.1165/rcmb.2019-0117OC.

Obraztsova K, Mukhitov A, Basil MC, Katzen J, Carl J, Beers MF, Morrisey EE, Krymskaya VP: Abnormal alveolar architecture in lymphangioleiomymatosis (LAM) lungs is a result of defective epithelial-mesenchymal crosstalk. American Thoracic Society May 2020 Notes: Submitted to American Thoracic Society International Conference, May 2020, Philadelphia, PA.

Evans JF, Rue RW, Mukhitov AR, Obraztsova K, Smith CJ, Krymskaya VP : Inhibition of growth of TSC2-null cells by a PI3K/mTOR inhibitor but not by a selective MNK1/2 inhibitor Biomolecules: Molecular Pathology, Molecular Mechanisms of Lung Diseases 10(1): 28, Dec 2019 Notes: doi: 10.3390/biom10010028.

Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, Arenas DJ, Ruth JR, Nabel CS, Stone K, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Jordan MB, Cohen AD, Krymskaya V, Rubenstein A, Betts MR, Kambayashi T, van Rhee F, Uldrick TS: Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. The Journal of clinical investigation 129(10): 4451-4463, Aug 2019 Notes: doi: 10.1172/JCI126091.

Abdelwahab EMM, Pal S, Kvell K, Sarosi V, Bai P, Rue R, Krymskaya V, McPhail D, Porter A, Pongracz JE : Mitochondrial dysfunction is a key determinant of the rare lung disease lymphangioleiomyomatosis and provides a novel therapeutic target Oncogene 38(16): 3093-3101, Apr 2019 Notes: doi: 10.1038/s41388-018-0625-1.

Obraztsova K, Hur SK, Rue R, Bartolomei MS, Evans JF, Krymskaya VP : IGF2 as a potential novel therapeutic target for rapamycin-insensitive LAM patients International Rare Lung Diseases Research Conference and LAMposium, Cincinnati, OH Sep 2018.

back to top
Last updated: 04/16/2021
The Trustees of the University of Pennsylvania